Serum biomarkers of inflammation and vascular damage upon SARS-Cov-2 mRNA vaccine in patients with thymic epithelial tumors.
SARS-CoV-2
inflammation
mRNA vaccine
thymic epithelial tumors
vascular damage
Journal
Clinical chemistry and laboratory medicine
ISSN: 1437-4331
Titre abrégé: Clin Chem Lab Med
Pays: Germany
ID NLM: 9806306
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
received:
13
11
2023
accepted:
03
01
2024
medline:
17
1
2024
pubmed:
17
1
2024
entrez:
17
1
2024
Statut:
aheadofprint
Résumé
Thymic epithelial tumors (TET) patients are at high risk of autoimmune and hypoimmune complications. Limited evidence is available on the potential risk of immune-related and inflammatory reactions induced by SARS-Cov-2 vaccine in this patient population. In order to identify subjects at higher risk for vaccine complications, we prospectively evaluated a panel of serum biomarkers related to inflammation (TNF-α, IL-1β, -6, -10, -12, and -17A, IFN-α, β and γ, MPO, MMP-9), and vascular damage (E- and P-selectin, VEGF-A, P-ANCA and MCP-1) in 44 TET patients and in 30 healthy controls along the whole SARS-Cov-2 vaccine cycle. About 50 % of subjects (either TET and controls) showed an increase of serum biochemical markers of inflammation and endothelial damage with a large heterogeneity of values. Such increase appeared early, after the first dose in control subjects and later, after the second dose in TET patients (in which we observed mainly an increase of inflammatory biomarkers). The values normalized after about 3 months and did not increase after the third, booster dose. No autoimmune or vascular complications were observed in the study subjects and no difference was observed in terms of vaccine response among subjects showing serum biomarkers increase and those who experienced no changes. Our data highlight the relevance of Sars-Cov-2 vaccine in TET patients, as it resulted safe and prevented severe COVID-19. However, further studies are awaited to explore the mechanisms and the potential consequences of the observed increase of serum inflammatory and vascular damage biomarkers.
Identifiants
pubmed: 38232092
pii: cclm-2023-1283
doi: 10.1515/cclm-2023-1283
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 the author(s), published by De Gruyter, Berlin/Boston.
Références
Sahin, U, Muik, A, Vogler, I, Derhovanessian, E, Kranz, LM, Vormehr, M, et al.. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 2021;595:572–7. https://doi.org/10.1038/s41586-021-03653-6 .
doi: 10.1038/s41586-021-03653-6
Haas, EJ, Angulo, FJ, McLaughlin, JM, Anis, E, Singer, SR, Khan, F, et al.. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet 2021;397:1819–29. https://doi.org/10.1016/s0140-6736(21)00947-8 .
doi: 10.1016/s0140-6736(21)00947-8
Marx, A, Chan, JKC, Chalabreysse, L, Dacic, S, Detterbeck, F, French, CA, et al.. The 2021 WHO classification of tumors of the thymus and mediastinum: what is new in thymic epithelial, germ cell, and mesenchymal tumors? J Thorac Oncol 2022;17:200–13. https://doi.org/10.1016/j.jtho.2021.10.010 .
doi: 10.1016/j.jtho.2021.10.010
Zhao, C, Rajan, A. Immune checkpoint inhibitors for treatment of thymic epithelial tumors: how to maximize benefit and optimize risk? Mediastinum 2019;3:35. https://doi.org/10.21037/med.2019.08.02 .
doi: 10.21037/med.2019.08.02
Vojdani, A, Vojdani, E, Kharrazian, D. Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol 2021;19:617089. https://doi.org/10.3389/fimmu.2020.617089 .
doi: 10.3389/fimmu.2020.617089
Chen, Y, Xu, Z, Wang, P, Li, XM, Shuai, ZW, Ye, DQ, et al.. New-onset autoimmune phenomena post-COVID-19 vaccination. Immunology 2022;165:386–401. https://doi.org/10.1111/imm.13443 .
doi: 10.1111/imm.13443
Malfitano, AM, D’Esposito, V, De Placido, P, Tortora, M, Ottaviano, M, Pietroluongo, E, et al.. Immunological signature of patients with thymic epithelial tumors and Good syndrome. Front Immunol 2022;13:908453. https://doi.org/10.3389/fimmu.2022.908453 .
doi: 10.3389/fimmu.2022.908453
Pietroluongo, E, De Placido, P, Picozzi, F, Morra, R, Tortora, M, Del Deo, V, et al.. Multidisciplinary approach for rare thoracic tumors during COVID-19 pandemic. Mediastinum 2022;7:8. https://doi.org/10.21037/med-21-47 .
doi: 10.21037/med-21-47
Pietroluongo, E, De Placido, P, Tortora, M, Martinelli, C, Viggiano, A, Saponaro, MR, et al.. Impaired seroconversion after severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with thymic epithelial tumors. J Thorac Oncol 2023;18:1399–407. https://doi.org/10.1016/j.jtho.2023.06.015 .
doi: 10.1016/j.jtho.2023.06.015
Ballman, M, Swift, S, Mullenix, C, Mallory, Y, Zhao, C, Szabo, E, et al.. Tolerability of coronavirus disease 2019 vaccines, BNT162b2 and mRNA-1273, in patients with thymic epithelial tumors. JTO Clin Res Rep 2021;2:100229. https://doi.org/10.1016/j.jtocrr.2021.100229 .
doi: 10.1016/j.jtocrr.2021.100229
Cernera, G, Gelzo, M, De Placido, P, Ottaviano, M, Pietroluongo, E, Raia, M, et al.. Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID vaccine booster strongly enhanced the immune response. Front Immunol 2023;14:1233056. https://doi.org/10.3389/fimmu.2023.1233056 .
doi: 10.3389/fimmu.2023.1233056
Trougakos, IP, Terpos, E, Alexopoulos, H, Politou, M, Paraskevis, D, Scorilas, A, et al.. Adverse effects of COVID-19 mRNA vaccines: the spike hypothesis. Trends Mol Med 2022;28:542–54. https://doi.org/10.1016/j.molmed.2022.04.007 .
doi: 10.1016/j.molmed.2022.04.007
Ostrowski, SR, Søgaard, OS, Tolstrup, M, Stærke, NB, Lundgren, J, Østergaard, L, et al.. Inflammation and platelet activation after COVID-19 vaccines – possible mechanisms behind vaccine-induced immune thrombocytopenia and thrombosis. Front Immunol 2021;12:779453. https://doi.org/10.3389/fimmu.2021.779453 .
doi: 10.3389/fimmu.2021.779453
Engelmann, B, Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 2013;13:34–45. https://doi.org/10.1038/nri3345 .
doi: 10.1038/nri3345
Gorog, DA, Storey, RF, Gurbel, PA, Tantry, US, Berger, JS, Chan, MY, et al.. Current and novel biomarkers of thrombotic risk in COVID-19: a consensus statement from the international COVID-19 thrombosis biomarkers colloquium. Nat Rev Cardiol 2022;19:475–95. https://doi.org/10.1038/s41569-021-00665-7 .
doi: 10.1038/s41569-021-00665-7
Cortese, P, Amato, F, Davino, A, De Franchis, R, Esposito, S, Zollo, I, et al.. Humoral and cellular immune response to Sars-CoV-2 vaccine in a cohort of family pediatricians from Southern Italy. Cells 2023;12:1447. https://doi.org/10.3390/cells12111447 .
doi: 10.3390/cells12111447
Severa, M, Rizzo, F, Sinigaglia, A, Ricci, D, Etna, MP, Cola, G, et al.. A specific anti-COVID-19 BNT162b2 vaccine-induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients. Clin Transl Immunol 2023;12:e1434. https://doi.org/10.1002/cti2.1434 .
doi: 10.1002/cti2.1434
Cacciapuoti, S, De Rosa, A, Gelzo, M, Megna, M, Raia, M, Pinchera, B, et al.. Immunocytometric analysis of COVID patients: a contribution to personalized therapy? Life Sci 2020;261:118355. https://doi.org/10.1016/j.lfs.2020.118355 .
doi: 10.1016/j.lfs.2020.118355
Gelzo, M, Castaldo, A, Giannattasio, A, Scalia, G, Raia, M, Esposito, MV, et al.. MIS-C: a COVID-19-as sociated condition between hypoimmunity and hyperimmunity. Front Immunol 2022;13:985433. https://doi.org/10.3389/fimmu.2022.985433 .
doi: 10.3389/fimmu.2022.985433
Gelzo, M, Giannattasio, A, Maglione, M, Muzzica, S, D’Anna, C, Scialò, F, et al.. Biomarkers of endothelial damage in distinct phase of multisystem inflammatory syndrome in children. Metabolites 2022;12:680. https://doi.org/10.3390/metabo12080680 .
doi: 10.3390/metabo12080680
Scalia, G, Raia, M, Gelzo, M, Cacciapuoti, S, Rosa, A, Pinchera, B, et al.. Lymphocyte population changes at two time points during the acute period of COVID-19 infection. J Clin Med 2022;11:4306. https://doi.org/10.3390/jcm11154306 .
doi: 10.3390/jcm11154306
Thammathiwat, T, Banjongjit, A, Iampenkhae, K, Townamchai, N, Kanjanabuch, T. ANCA associated glomerulonephritis following SARS-CoV-2 vaccination: a case series and systematic review. Vaccines 2023;11:983. https://doi.org/10.3390/vaccines11050983 .
doi: 10.3390/vaccines11050983
Shakoor, MT, Birkenbach, MP, Lynch, M. ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis 2021;78:611–3. https://doi.org/10.1053/j.ajkd.2021.06.016 .
doi: 10.1053/j.ajkd.2021.06.016
Talotta, R. Impaired VEGF-A-mediated neurovascular crosstalk induced by SARS-CoV-2 spike protein: a potential hypothesis explaining long COVID-19 symptoms and COVID-19 vaccine side effects? Microorganisms 2022;10:2452. https://doi.org/10.3390/microorganisms10122452 .
doi: 10.3390/microorganisms10122452
Peng, CH, Lin, CL, Yang, CW, Shueh, S, Huang, CC. Vascular endothelial growth factor may provide additional values to C-reactive protein and anti-myeloperoxidase titer as a parameter for evaluating disease activity in anti-myeloperoxidase associated vasculitis. Ren Fail 2003;25:1057–66. https://doi.org/10.1081/jdi-120026042 .
doi: 10.1081/jdi-120026042
Mezache, L, Struckman, HL, Greer-Short, A, Baine, S, Györke, S, Radwański, PB, et al.. Vascular endothelial growth factor promotes atrial arrhythmias by inducing acute intercalated disk remodeling. Sci Rep 2020;10:20463. https://doi.org/10.1038/s41598-020-77562-5 .
doi: 10.1038/s41598-020-77562-5